Chime Biologics announced today that it has secured a total commitment of $190 million Series A+ investment from institutional investors in which over $100 million investment has already been closed today. This round financing was led by VMS Group and followed by Fidelity International and Panacea Venture. Earlier in February 2020 Chime Biologics has just completed its Series A financing of $125 million.
Chime Biologics signed a contract with Wuhan East Lake High-tech Zone, and the two sides will jointly promote Chime Biologics’ large-scale biological world-class Contract Development and Manufacturing Organization (CDMO) factory to launch and start as soon as possible.
Chime Biologics today announced operations as an independent and stand-alone biologics CDMO company. With the separation from JHL Biotech complete, Chime Biologics is now focused on delivering the world-class biologics CDMO services to its global clients and business partners.
JHL Biotech has made a strategic decision benefitting all of its patients, shareholders, employees and the company to restructure JHL Biologics and spinoff its China Facility to have a stronger presence in China, with new and additional investment opportunities. With the separation, Chime Biologics (a BVI Company, which is the corporate office of XiKang Wuhan) will have one of the largest and most thorough CDMO capabilities in China Biologics Market. Chime will continue to provide services to clients and business partners from early to late-stage commercial development and manufacturing.
CredSimple, the leading cloud-based healthcare credential verification organization, today announced the acquisition of Glenridge Health, a premier technology-enabled provider network management solutions company. This acquisition strategically expands CredSimple's capabilities to include comprehensive provider network development and management services. It also marks a critical investment towards offering CredSimple customers a more vertically integrated and streamlined solution that will allow them to efficiently analyze, build, and manage their networks, while mitigating the burden of provider credentialing through automation.
JHL remains well-positioned to capture growing market opportunities and implement our long-term strategic plan for sustainable growth, including focusing on executing the rollout of our biosimilar pipeline and the global expansion of our CDMO business. This plan will create long-term value for our shareholders, bolster our strong financial position, and capitalize on the market’s continued optimism in our business.
ADMA Biologics, Inc. (NASDAQ: ADMA) announces that the U.S. Food and Drug Administration (“FDA”) has approved ASCENIV™, Immune Globulin Intravenous, Human – slra 10% Liquid, formerly referred to as RI-002. ASCENIV™ is an Intravenous Immune Globulin (“IVIG”) drug product for the treatment of Primary Humoral Immunodeficiency Disease (“PIDD” or “PI”) in adults and adolescents (12 to 17 years of age). The Company anticipates having the product available for commercial launch during the second half of 2019.
Strand Life Sciences announced an agreement to acquire the India medical diagnostics business of Quest Diagnostics, the world’s leading provider of diagnostic information services.
ADMA Biologics announces that it has received formal notice from the FDA of the successful close-out for the April 2018 compliance inspection of the Boca Raton, FL production facility. This is the first EIR issued to the site since 2012.
Quest Analytics, the leading provider of network access and adequacy services to health plans and insurance regulatory agencies, today announced that it has acquired BetterDoctor, the nation’s most accurate provider data management platform. Together, the companies will provide the first comprehensive platform that enables health plans to optimize their member experience while complying with federal and state regulations for network adequacy and accuracy.
Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc. (NASDAQ:JUNO) today announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Juno. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash and marketable securities acquired and Juno shares already owned by Celgene (approximately 9.7% of outstanding shares). The transaction was approved by the boards of directors of both companies.
JHL Biotech Inc. (Stock Code: 6540.TWO) announced today that it has submitted a Phase 1 Clinical Trial Application to the Dutch Healthcare Authority for its proposed dornase alfa biosimilar, JHL1922, to improve pulmonary function of cystic fibrosis patients.
JHL Biotech, at December 15, 2017, has submitted a Phase I Clinical Trial Application (“CTA”) to European authorities for its proposed bevacizumab biosimilar, JHL1149.
ADMA Biologics announced today that its acquisition of the assets of Biotest Pharmaceuticals Corporation’s Therapy Business Unit (BTBU) has been completed. ADMA has assumed operational control of the assets and has formally commenced integration activities.
JHL Biotech Inc. (Stock Code: 6540.TWO) is announcing that its Clinical Trial Application for use of JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by the China Food and Drug Administration.
JHL Biotech Inc. (Stock Code: 6540.TWO) today announced that the first patient has been dosed in the company's Phase I clinical trial of JHL1101 (a proposed rituximab biosimilar) in rheumatoid arthritis patients.
HyperMed Imaging, Inc. announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) for the company’s new medical imaging device called HyperView™. The HyperView product is a handheld, battery operated, portable diagnostic imaging device that is used to assess tissue oxygenation without contacting the patient
Sanofi (EURONEXT: SAN and NYSE: SNY), a global healthcare leader and JHL Biotech, Inc. (6540.TWO), a biopharmaceutical company with development and manufacturing facilities in Wuhan and Taiwan, announced today a strategic alliance to collaborate on the development and commercialization of biological therapeutics in China and with potential international expansion.
CAR-Ts won’t be on the market before next year, but the technology arms race inspired by the prospect of a multibillion-dollar market has inspired a group of prominent investigators to design a new, 3.0 model in the lab that includes a built-in checkpoint mechanism. And it worked like a charm in mouse models of solid tumors - a critical hurdle that the key players have been struggling to clear.
JHL Biotech (TWEM: 6540) and GE Healthcare’s Life Sciences business (NYSE: GE) are proud to announce mechanical completion of JHL Biotech’s JHL-1 biopharmaceutical manufacturing facility in the Biolake area of Wuhan, China.